Business
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
CHICAGO, March 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA
About this update from The Oncology Institute, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/161e1e95c26abdc999de1b2e79162528"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejDfvw4bmdybf4MS7DN7pQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/161e1e95c26abdc999de1b2e79162528","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FVA0589rWvWm4kWZISmHPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/161e1e95c26abdc999de1b2e79162528","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, March 11, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex identify actionable findings that are missed by more limited standard in-network testing.","length":644,"tagName":"p"},{"type":"text","content":"While organizations like ASCO® and the NCCN® strongly advocate for CGP to guide precision therapies, current guidelines often lack specificity regarding the exact composition or essential features required within these panels. This research demonstrates that CGP value extends far beyond simple panel size, highlighting the utility of advanced testing features to more fully capture clinically relevant findings.","length":412,"tagName":"p"},{"type":"text","content":"In the study, 12% (approximately 1 in 8) of patients across the pilot and expanded cohorts had potentially actionable findings associated with an approved therapy identified solely through advanced Tempus features—such as tumor-normal matching, RNA sequencing, and liquid biopsy reflex testing—that would otherwise have been missed by less comprehensive tests.","length":360,"tagName":"p"},{"type":"text","content":""This study demonstrates a clear clin...